Novartis/Schering AG Re-Evaluating PTK/ZK Development Due To Low Probability Of Survival Benefit
This article was originally published in The Pink Sheet Daily
Executive Summary
Firms plan to reconsider NDA submission strategy after interim analysis of CONFIRM-2 trial suggests PTK/ZK 787 is unlikely to yield survival benefit in second-line metastatic colorectal cancer.
You may also be interested in...
Novartis Oncology President David Epstein: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
Novartis’ oncology chief discusses expectations for Tasigna and outlook for late-stage pipeline.
Novartis Oncology President David Epstein: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)
Novartis’ oncology chief discusses expectations for Tasigna and outlook for late-stage pipeline.
Novartis/Schering AG's Vatalanib Efficacy Not CONFIRMed; Filing Delayed Until 2007
Colorectal cancer agent fails to meet primary endpoint of central radiology review-assessed progression-free survival in the CONFIRM-1 trial, Novartis says. The company expects data on overall survival for the agent, also known as PTK-ZK, to be available in the second half of 2006.